Aclarion (ACON) Competitors $6.99 +0.04 (+0.58%) Closing price 08/1/2025 03:59 PM EasternExtended Trading$7.03 +0.04 (+0.57%) As of 08/1/2025 07:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesSEC FilingsShort InterestTrendsBuy This Stock ACON vs. BRTX, SSY, MGRX, BGLC, DHAC, ATIP, OTRK, NIVF, OPGN, and BACKShould you be buying Aclarion stock or one of its competitors? The main competitors of Aclarion include Biorestorative Therapies (BRTX), SunLink Health Systems (SSY), Mangoceuticals (MGRX), BioNexus Gene Lab (BGLC), Digital Health Acquisition (DHAC), ATI Physical Therapy (ATIP), Ontrak (OTRK), NewGenIvf Group (NIVF), OpGen (OPGN), and IMAC (BACK). These companies are all part of the "healthcare" industry. Aclarion vs. Its Competitors Biorestorative Therapies SunLink Health Systems Mangoceuticals BioNexus Gene Lab Digital Health Acquisition ATI Physical Therapy Ontrak NewGenIvf Group OpGen IMAC Aclarion (NASDAQ:ACON) and Biorestorative Therapies (NASDAQ:BRTX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, media sentiment, profitability, earnings, institutional ownership and dividends. Which has stronger valuation and earnings, ACON or BRTX? Aclarion has higher earnings, but lower revenue than Biorestorative Therapies. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAclarion$54.60K74.51-$6.99MN/AN/ABiorestorative Therapies$400K26.44-$8.98M-$1.47-0.96 Which has more risk and volatility, ACON or BRTX? Aclarion has a beta of 1.34, suggesting that its share price is 34% more volatile than the S&P 500. Comparatively, Biorestorative Therapies has a beta of 76.73, suggesting that its share price is 7,573% more volatile than the S&P 500. Is ACON or BRTX more profitable? Biorestorative Therapies has a net margin of -3,093.61% compared to Aclarion's net margin of -12,227.10%. Aclarion's return on equity of -126.89% beat Biorestorative Therapies' return on equity.Company Net Margins Return on Equity Return on Assets Aclarion-12,227.10% -126.89% -106.61% Biorestorative Therapies -3,093.61%-129.47%-86.02% Does the media prefer ACON or BRTX? In the previous week, Aclarion had 1 more articles in the media than Biorestorative Therapies. MarketBeat recorded 1 mentions for Aclarion and 0 mentions for Biorestorative Therapies. Aclarion's average media sentiment score of 0.00 equaled Biorestorative Therapies'average media sentiment score. Company Overall Sentiment Aclarion Neutral Biorestorative Therapies Neutral Do institutionals & insiders believe in ACON or BRTX? 7.5% of Aclarion shares are owned by institutional investors. Comparatively, 69.4% of Biorestorative Therapies shares are owned by institutional investors. 0.8% of Aclarion shares are owned by company insiders. Comparatively, 25.5% of Biorestorative Therapies shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Do analysts prefer ACON or BRTX? Aclarion presently has a consensus target price of $11,758.50, indicating a potential upside of 168,118.88%. Biorestorative Therapies has a consensus target price of $18.00, indicating a potential upside of 1,176.60%. Given Aclarion's higher possible upside, research analysts clearly believe Aclarion is more favorable than Biorestorative Therapies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aclarion 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Biorestorative Therapies 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryBiorestorative Therapies beats Aclarion on 8 of the 13 factors compared between the two stocks. Get Aclarion News Delivered to You Automatically Sign up to receive the latest news and ratings for ACON and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ACON and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ACON vs. The Competition Export to ExcelMetricAclarionMedical Services IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.05M$7.18B$5.49B$9.52BDividend YieldN/A2.90%4.73%4.09%P/E RatioN/A64.1328.7823.81Price / Sales74.5133.83372.2066.04Price / CashN/A25.7735.4557.96Price / Book0.148.618.275.54Net Income-$6.99M$239.96M$3.25B$259.28M7 Day Performance-6.43%-5.48%-3.70%-4.64%1 Month Performance-6.99%-3.73%4.34%4.41%1 Year Performance-99.73%18.27%25.90%17.95% Aclarion Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ACONAclarion1.4909 of 5 stars$6.99+0.6%$11,758.50+168,118.9%-99.7%$4.05M$54.60K0.007High Trading VolumeBRTXBiorestorative Therapies3.5123 of 5 stars$1.57-3.1%$18.00+1,046.5%-7.8%$12.16M$400K-1.077SSYSunLink Health Systems1.7222 of 5 stars$1.32-2.9%N/A+22.4%$9.58M$31.09M9.431,376Gap DownHigh Trading VolumeMGRXMangoceuticalsN/A$1.71-1.2%N/A-98.0%$8.94M$620K-0.373Positive NewsBGLCBioNexus Gene Lab0.2249 of 5 stars$4.55-7.1%N/A+43.2%$8.80M$9.27M0.0030News CoverageShort Interest ↑Gap DownDHACDigital Health AcquisitionN/A$1.33-2.2%N/A-43.8%$4.79MN/A0.002,021Gap UpATIPATI Physical Therapy0.1268 of 5 stars$0.68+87.5%N/A-89.1%$2.98M$741.86M-0.045,600News CoverageGap UpOTRKOntrak2.1483 of 5 stars$0.53-10.0%$24.00+4,463.6%-92.0%$2.46M$10.85M-0.03250Upcoming EarningsShort Interest ↑NIVFNewGenIvf GroupN/A$0.52+0.0%N/A-99.8%$2.25M$5.43M0.00N/AGap UpOPGNOpGenN/A$0.04+0.8%N/A-98.7%$396K$2.67M0.00100Short Interest ↓BACKIMACN/A$0.06flatN/A-96.1%$124K$72.05K0.00180Upcoming EarningsGap Up Related Companies and Tools Related Companies Biorestorative Therapies Competitors SunLink Health Systems Competitors Mangoceuticals Competitors BioNexus Gene Lab Competitors Digital Health Acquisition Competitors ATI Physical Therapy Competitors Ontrak Competitors NewGenIvf Group Competitors OpGen Competitors IMAC Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ACON) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | SponsoredTrump’s crypto advisor may have revealed the next big crypto opportunityWhile investors chase Bitcoin toward $100K, D.C. insiders are quietly loading up on something else. One of Tru...Weiss Ratings | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aclarion, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aclarion With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ACON Stock Alerts